Childhood cancers (all types): lines of therapy
3 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Special situations
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Survivorship | Lifelong follow-up for late effects on heart, fertility, growth and second cancers, with a survivorship care plan; trials that reduce therapy where cure rates are high. | 58 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Leukaemias | Risk-stratified multi-agent chemotherapy over two to three years for ALL, with immunotherapy (blinatumomab, CAR-T) for high-risk or relapsed disease. See the ALL page. | 85 | ||
| All comers | Solid tumours | Surgery, chemotherapy and radiotherapy by risk group in cooperative group protocols; anti-GD2 antibody for high-risk neuroblastoma. See the neuroblastoma, Wilms, sarcoma and brain tumour pages. | 82 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.